Literature DB >> 27435858

Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.

Fatima Qaiser1, Janeen H Trembley2,3,4, Sarah Sadiq1, Iqbal Muhammad5, Rubina Younis5, Shoaib Naiyar Hashmi6, Badar Murtaza7, Thomas S Rector2, Abdul Khaliq Naveed1,8, Khalil Ahmed9,10,11.   

Abstract

Protein kinase CK2 plays a critical role in cell growth, proliferation, and suppression of cell death. CK2 is overexpressed, especially in the nuclear compartment, in the majority of cancers, including prostate cancer (PCa). CK2-mediated activation of transcription factor nuclear factor kappa B (NF-κB) p65 is a key step in cellular proliferation, resulting in translocation of NF-κB p65 from the cytoplasm to the nucleus. As CK2 expression and activity are also elevated in benign prostatic hyperplasia (BPH), we sought to increase the knowledge of CK2 function in benign and malignant prostate by examination of the relationships between nuclear CK2 and nuclear NF-κB p65 protein expression. The expression level and localization of CK2α and NF-κB p65 proteins in PCa and BPH tissue specimens was determined. Nuclear CK2α and NF-κB p65 protein levels are significantly higher in PCa compared with BPH, and these proteins are positively correlated with each other in both diseases. Nuclear NF-κB p65 levels correlated with Ki-67 or with cytoplasmic NF-κB p65 expression in BPH, but not in PCa. The findings provide information that combined analysis of CK2α and NF-κB p65 expression in prostate specimens relates to the disease status. Increased nuclear NF-κB p65 expression levels in PCa specifically related to nuclear CK2α levels, indicating a possible CK2-dependent relationship in malignancy. In contrast, nuclear NF-κB p65 protein levels related to both Ki-67 and cytoplasmic NF-κB p65 levels exclusively in BPH, suggesting a potential separate impact for NF-κB p65 function in proliferation for benign disease as opposed to malignant disease.

Entities:  

Keywords:  BPH; Biomarker; CK2; Ki-67; Nuclear factor kappa B; Prostate cancer; RELA

Mesh:

Substances:

Year:  2016        PMID: 27435858      PMCID: PMC6668611          DOI: 10.1007/s11010-016-2765-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  48 in total

Review 1.  The Ki-67 protein: fascinating forms and an unknown function.

Authors:  E Endl; J Gerdes
Journal:  Exp Cell Res       Date:  2000-06-15       Impact factor: 3.905

2.  Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II.

Authors:  D Wang; S D Westerheide; J L Hanson; A S Baldwin
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

3.  Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells.

Authors:  Cécile Le Page; Ismael Hervé Koumakpayi; Laurent Lessard; Fred Saad; Anne-Marie Mes-Masson
Journal:  Prostate       Date:  2005-12-01       Impact factor: 4.104

4.  Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer.

Authors:  R Romieu-Mourez; E Landesman-Bollag; D C Seldin; A M Traish; F Mercurio; G E Sonenshein
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

5.  Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells.

Authors:  R A Faust; G Niehans; M Gapany; D Hoistad; D Knapp; D Cherwitz; A Davis; G L Adams; K Ahmed
Journal:  Int J Biochem Cell Biol       Date:  1999-09       Impact factor: 5.085

6.  Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells.

Authors:  Raphaëlle Romieu-Mourez; Esther Landesman-Bollag; David C Seldin; Gail E Sonenshein
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

7.  Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells.

Authors:  Sean F Eddy; Shangqin Guo; Elizabeth G Demicco; Raphaëlle Romieu-Mourez; Esther Landesman-Bollag; David C Seldin; Gail E Sonenshein
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

8.  Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer.

Authors:  Mathieu Laramas; Dominique Pasquier; Odile Filhol; François Ringeisen; Jean-Luc Descotes; Claude Cochet
Journal:  Eur J Cancer       Date:  2007-01-30       Impact factor: 9.162

9.  NF-kappa B nuclear localization and its prognostic significance in prostate cancer.

Authors:  L Lessard; A-M Mes-Masson; L Lamarre; L Wall; J-B Lattouf; F Saad
Journal:  BJU Int       Date:  2003-03       Impact factor: 5.588

10.  Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells.

Authors:  Junghan Suh; Faribourz Payvandi; Leonard C Edelstein; Peter S Amenta; Wei-Xing Zong; Céline Gélinas; Arnold B Rabson
Journal:  Prostate       Date:  2002-08-01       Impact factor: 4.104

View more
  7 in total

Review 1.  CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer.

Authors:  Janeen H Trembley; Betsy T Kren; Md Joynal Abedin; Rachel I Vogel; Claire M Cannon; Gretchen M Unger; Khalil Ahmed
Journal:  Pharmaceuticals (Basel)       Date:  2017-02-21

2.  CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.

Authors:  Khalil Ahmed; Betsy T Kren; Md Joynal Abedin; Rachel I Vogel; Daniel P Shaughnessy; Lucas Nacusi; Vicci L Korman; Yingming Li; Scott M Dehm; Cheryl L Zimmerman; Gloria A Niehans; Gretchen M Unger; Janeen H Trembley
Journal:  Oncotarget       Date:  2016-09-20

Review 3.  CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.

Authors:  Melissa M J Chua; Charina E Ortega; Ayesha Sheikh; Migi Lee; Hussein Abdul-Rassoul; Kevan L Hartshorn; Isabel Dominguez
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-28

4.  CK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NFκB p65 Expression.

Authors:  Janeen H Trembley; Betsy T Kren; Md J Abedin; Daniel P Shaughnessy; Yingming Li; Scott M Dehm; Khalil Ahmed
Journal:  Pharmaceuticals (Basel)       Date:  2019-06-14

5.  An Integrative Pan-Cancer Analysis of the Prognostic and Immunological Role of Casein Kinase 2 Alpha Protein 1 (CSNK2A1) in Human Cancers: A Study Based on Bioinformatics and Immunohistochemical Analysis.

Authors:  Ruohao Wu; Wenting Tang; Kunyin Qiu; Pinggan Li; Yu Li; Dongfang Li; Zhanwen He
Journal:  Int J Gen Med       Date:  2021-09-29

Review 6.  CSNK2 in cancer: pathophysiology and translational applications.

Authors:  Scott W Strum; Laszlo Gyenis; David W Litchfield
Journal:  Br J Cancer       Date:  2021-11-12       Impact factor: 9.075

Review 7.  Protein kinase CK2 - diverse roles in cancer cell biology and therapeutic promise.

Authors:  Janeen H Trembley; Betsy T Kren; Muhammad Afzal; George A Scaria; Mark A Klein; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2022-09-17       Impact factor: 3.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.